Trial Profile
Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs GLS 5300 (Primary)
- Indications Middle East respiratory syndrome coronavirus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Inovio Pharmaceuticals
- 22 Dec 2022 Status changed from active, no longer recruiting to completed.
- 18 Nov 2022 Planned End Date changed from 15 Jun 2024 to 24 Nov 2022.
- 18 Nov 2022 Planned primary completion date changed from 15 Jun 2024 to 24 Nov 2022.